Effect of Oral Administration of Dietary Antioxidant Supplements in Patients with Chronic Hepatitis C
American Journal of Clinical and Experimental Medicine
Volume 3, Issue 4, July 2015, Pages: 137-141
Received: May 17, 2015;
Accepted: May 23, 2015;
Published: Jun. 6, 2015
Views 3713 Downloads 85
Torricelli Piera, Department SPES, University of Molise, Campobasso, Italy
Antonelli Francesco, University of Tor Vergata, Department of Biology, Rome, Italy
Ferorelli Pasquale, University of Tor Vergata, Department of Biology, Rome, Italy
De Martino Angelo, University of Tor Vergata, Department of Biology, Rome, Italy
Shevchenko Anna, People’s Friendship University of Russia, Department of Sciences, Moscow, Russia
Beninati Simone, University of Tor Vergata, Department of Biology, Rome, Italy
In a prospective, randomized and single-blinded clinical trial, we compared patients with Chronic hepatitis C (CHC) orally treated with sucrose diluted with water (1:2) twice a day for 56 days (control group), with patients orally treated with four antioxidant dietary supplements rich in vitamin B5, B9, C, D, citric, pyruvic, and tartaric acids and carbohydrates (CCEP: Citexivir, Citozym, Ergozym Plus and Propulzym). The efficacy of treatment was evaluated once a week for 8 weeks, by monitoring changes in the activities of circulating Alanine aminotransferase (ALT), Aspartate aminotransferase (AST) and Gamma-glutamyl transferase (GGT) as markers of liver damage. After a treatment of 84 days the viral title was evaluated through the HCV-RNA compared with the levels of anti-C100-3. The security and tolerability of the treatment were evaluated on the basis of clinical adverse events and results of laboratory tests. The experimental data obtained showed that the oral treatment of patients suffering from HCV infection of genotype 1, with CCEP, markedly influenced the values of the three enzymatic markers of hepatic disease. The data presented also showed the reduction of viral replication evidenced by the rate of HCV-RNA levels. As reported by others, we confirmed the low reliability of the research of anti-C100-3. This research is not meant to suggest the treatment reported as a therapy for the treatment of HCV infection, but data obtained may tend towards the possibility of administration of a dietary supplement such as CCEP in support of the official drug therapy of CHC in the nutritional care of HCV patients.
De Martino Angelo,
Effect of Oral Administration of Dietary Antioxidant Supplements in Patients with Chronic Hepatitis C, American Journal of Clinical and Experimental Medicine.
Vol. 3, No. 4,
2015, pp. 137-141.
Lauer GM, Walker, B D Hepatitis C virus infection. N. Engl. J. Med. 2001; 345(1): 41–52.
Pol S, Vallet-Pichard A, Corouge M, Mallet VO. Hepatitis C: epidemiology, diagnosis, natural history and therapy. Contrib Nephrol. 2012;176:1-9
Seronello S, Sheikh M Y, Choi J. Redox regulation of hepatitis C in nonalcoholic and alcoholic liver. Free Radic. Biol. Med. 2007;43:869–882.
Abdalla MY, Ahmad IM, Spitz DR, Schmidt WN, and Britigan BE. Hepatitis C virus-core and nonstructural proteins lead to different effects on cellular antioxidant defenses. J Med Virol 2005; 76: 489–497.
Larrea E, Beloqui O, Munos-Navas MA, Civeira MP, Prieto J. Superoxidedismutase in patients with chronic hepatitis C virus infection. Free Radic Biol Med 1998; 24:1235-1241.
von Herbay, A., et al. Vitamin E improves the aminotransferase status of patients suffering from viral hepatitis C: a randomized, double-blind, placebo-controlled study. Free. Radic. Res. 1997; 27:599–605.
Mahmood, S., et al. Effect of vitamin E on serum aminotransferase and thioredoxin levels in patients with viral hepatitis C. Free. Radic. Res. 2003; 37: 781–785.
Falasca, K., et al. Treatment with silybin–vitamin E–phospholipid complex in patients with hepatitis C infection. J. Med. Virol. 2008; 80:1900–1906.
Houglum, K., et al. A pilot study of the effects of D-α-tocopherol on hepatic stellate cell activation in chronic hepatitis C. Gastroenterology. 1997; 113:1069–1073.
Melhem, A., et al. Treatment of chronic hepatitis C virus infection via antioxidants: results of a phase I clinical trial. J. Clin. Gastroenterol. 2005; 39:737–742.
Morisco F, Vitaglione P, Carbone A, Stingo S, Scarpati S, Ascione A, Marmo R, Fogliano V, Caporaso N. Tomato-based functional food as interferon adjuvant in HCV eradication therapy. J Clin Gastroenterol. 2004;38(6):S118-120.
P. Torricelli, P. Ferorelli, A. De Martino, F. Antonelli, A. Shevchenko, S. Beninati. Regression of Carotid Plaques in Individuals at Low-to-intermediate Cardiovascular Risk Treated with Citozym and Propulzym. European Journal of Preventive Medicine. 2014; 2 (3): 33-37.
Saverymuttu SH, Joseph AE, Maxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J (Clin Res Ed).1986;292:13–15.
Han TS, van Leer EM, Seidell JC, Lean ME. Waist circumference action levels in the identification of cardiovascular risk factors: prevalence study in a random sample. BMJ. 1995;311:1401–1405.
Clancy A, Crowley B, Niesters H, Herra C. The development of a qualitative real-time RT-PCR assay or the detection of hepatitis C virus. Eur J Clin Microbiol Infect Dis. 2008;27(12):1177-1182
Butcher A, Aslam S, Hemyari P, Cowen U, Heilek G. HCV RNA detection in HCV antibody-positive patients with the COBAS AmpliPrep/COBAS TaqMan HCV test, v2.0 in comparison with FDA-approved nucleic acid tests. J Clin Virol. 2014;60(4):336-340.
Barbaro, G., et al. Serum ferritin and hepatic glutathione concentrations in chronic hepatitis C patients related to the hepatitis C virus genotype. J. Hepatol. 1999; 30:774–782.
Kageyama, F., et al. Successful interferon therapy reverses enhanced hepatic iron accumulation and lipid peroxidation in chronic hepatitis C. Am. J. Gastroenterol. 2000; 95:1041–1050.
Machida, K., et al. Hepatitis C virus infection activates the immunologic (type II) isoform of nitric oxide synthase and thereby enhances DNA damage and mutations of cellular genes. 2004; J. Virol. 2004; 78:8835–8843.
Barbaro, G., et al. Hepatic glutathione deficiency in chronic hepatitis C: quantitative evaluation in patients who are HIV positive and HIV negative and correlations with plasmatic and lymphocytic concentrations and with the activity of the liver disease. Am. J. Gastroenterol. 1996; 91:2569–2573.
Gabbay, E., et al. Antioxidant therapy for chronic hepatitis C after failure of interferon α results of phase II randomized, double-blind placebo controlled clinical trial. World J. Gastroenterol. 2007; 13:5317–5323.
Torricelli P., Ferorelli P., De Martino A., Antonelli F., Beninati S.. The Influence of Preventive Multiple Micronutrients Supplementation on Liver Steatosis in High-cholesterol Fed C57BL6/N Mice. American Journal of Life Sciences. 2013;1(2):55-60
Morii K1, Shimomura H, Nakagawa H, Hasui T, Tsuji T. Anti-C100-3 antibody status, viral genomic sequences, and clinical features in chronic hepatitic patients with hepatitis C virus RNA in sera. Acta Med Okayama. 1992;46(4):285-293.